Eikon Therapeutics is focused on advancing innovative therapeutics through the integration of engineering and scientific principles. The company employs a proprietary single-molecule tracking (SMT) platform that allows for the visualization of protein motion events in living cells at an unprecedented scale and speed. This technology enables researchers to measure the dynamics of protein populations, which is crucial for understanding the activity of novel pharmaceuticals. By combining SMT with artificial intelligence and advanced automation, Eikon can inventory molecular interactions with exceptional precision, thereby enhancing the discovery and development of new medicines.

In addition to SMT, Eikon Therapeutics is leveraging super-resolution microscopy techniques to visualize the dynamics of macromolecules within live cells. This approach builds on Nobel Prize-winning advancements in fluorescence microscopy, allowing for detailed observation of individual protein behaviors. The integration of these technologies not only facilitates a deeper understanding of cellular processes but also supports Eikon's therapeutic pipeline, which includes programs targeting serious diseases across oncology, immunology, and neuroscience. Through this innovative blend of engineering and biology, Eikon aims to address significant unmet medical needs and deliver impactful new therapies to patients.

United States

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Eikon Therapeutics

Company Details